Biomarker science just got a powerful new set of tools. A biotechnology company focused on ultrasensitive protein detection has taken a significant step forward in the race to identify neurodegenerative diseases earlier and more accurately. Spear Bio introduced three new diagnostic assays at the International Conference on Alzheimer’s and Parkinson’s Diseases, known as AD/PD 2026, held recently in Copenhagen. The debut marks a meaningful expansion of the company’s toolkit for researchers working to understand and ultimately stop some of the most devastating brain diseases affecting people today.
The three new tests target proteins that have become central to the scientific understanding of Alzheimer’s and Parkinson’s disease. Each one is designed to detect these proteins at extraordinarily low concentrations in blood plasma, opening the door to identifying disease-related changes long before clinical symptoms emerge. That kind of early biological signal is precisely what researchers and clinicians have been searching for as the field moves toward intervention at the preclinical stage. The potential to act sooner, before irreversible damage sets in, is what makes these tools so significant.
The Alzheimer’s biomarker test breaking new ground
The first of the new assays, targeting a form of tau protein known as brain-derived phosphorylated tau 217, has already been released to early adopters and represents a notable advance in Alzheimer’s research. It is currently the only test of its kind capable of fully quantifying this specific tau variant in plasma samples from both healthy individuals and those with Alzheimer’s disease.
The test operates without the wash steps that complicate many standard laboratory assays and requires just one microliter of diluted plasma to deliver results. Its ability to detect tau changes at concentrations as low as 25 femtograms per milliliter makes it a powerful tool for longitudinal studies where preserving sample volume is critical. For researchers tracking disease progression over months or years, that efficiency is not a minor convenience but a fundamental advantage.
New biomarker tools for Parkinson’s and related conditions
The other two assays introduced at the conference address a different but equally urgent need in neurodegenerative research. Both target alpha-synuclein, a protein whose abnormal accumulation is closely linked to Parkinson’s disease and a group of related conditions known as synucleinopathies. One assay measures the standard form of the protein while the other targets a phosphorylated version that has been associated with disease-related aggregation.
Both tests can detect multiple forms of alpha-synuclein at low-femtogram concentrations using only a single microliter of diluted sample. Importantly, neither test requires specialized laboratory equipment. They run on widely available instruments already found in most research settings, removing a significant barrier to adoption for laboratories that lack access to proprietary platforms.
For scientists working with biobanked samples collected over years of longitudinal research, the minimal sample volume requirement means they can run more tests on the same precious material without depleting their archives. That translates directly into richer and more comprehensive data from studies that may have taken years to build.
Expanding direct biomarker access across two continents
Alongside the product launches, Spear Bio announced the establishment of direct-to-customer operations in both North America and Europe. Previously, access to the company’s technology involved additional steps that could slow down the research process. The move to direct engagement is intended to streamline procurement, support, and data interpretation for the laboratories that rely on these tools most heavily.
The timing of the expansion coincides with growing momentum in the field of blood-based biomarker testing for brain diseases. As regulatory agencies and clinical guidelines increasingly recognize the value of these tests in early diagnosis and patient stratification, the demand for highly sensitive and accessible assay platforms is expected to grow substantially in the years ahead. Spear Bio is clearly positioning itself to meet that demand head-on.
